Investigating the Frequency and Outcome of Central Vein Sign and Paramagnetic Rim Lesions in Children With MOGAD

Read full text
Authors: Riccardo Nistri, Laura Cacciaguerra, Simone Sacco, Akash Virupakshaiah, Ermelinda De Meo, Nico Papinutto, Roland Henry, Hadas Meirson, Cheryl Hemingway, Thomas Rossor, Evangeline Wassmer, Liat Bensira
+11 more Li-tal Pratt, Asthik Biswas, Sniya Sudhakar, Kshitij Mankad, John J. Chen, S J Pittock, Frederik Barkhof, Olga Ciccarelli, Emmanuelle Waubant, Eoin P. Flanagan, Yael Hacohen
Cited by: 4
References: 37

Abstract

BACKGROUND AND OBJECTIVES: Central vein sign (CVS) is a common feature in multiple sclerosis (MS) lesions, but its frequency in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) varies significantly across studies. Paramagnetic rim lesions (PRLs) are described in MS, but not in MOGAD. Our goals were to evaluate the prevalence of PRLs and CVS in a large multicenter cohort of pediatric MOGAD. We compared CVS frequencies between acute vs remission phases, as well as with longitudinal dynamics of lesion evolution. METHODS: In this longitudinal retrospective multicenter study, clinical MRIs were assessed from pediatric patients with MOGAD, who had (1) ≥1 brain lesion, (2) susceptibility-based imaging (SBI), and (3) follow-up MRI at least 3 months apart. T2-weighted and fluid-attenuated inversion recovery sequences were analyzed for lesion detection and resolution. SBI was used to assess CVS and PRLs following North American Imaging in MS Cooperative criteria. RESULTS: < 0.001). No PRLs were identified. DISCUSSION: Lesion pathobiology in MOGAD is heterogeneous. CVS identified persistent rather than transient lesions, with resolution more common among CVS- lesions. The high frequency of confluent or multivein lesions limited the proportion suitable for CVS analysis. MRI timing influenced CVS detection, which was higher in remission, suggesting that time of acquisition contributes to variability across MOGAD studies. No PRLs were found, supporting their potential as biomarkers distinguishing MOGAD from MS.

Fields of Study & Subjects

Vascular Malformations and Hemangiomas Immunodeficiency and Autoimmune Disorders Cystic Fibrosis Research Advances

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
3
Pages
e214410–e214410
Publication date
9 January 2026
Language
EN